Live Earnings Conference Call: Biofrontera's Q1 2025 earnings call is happening now. NASDAQ:BFRI Biofrontera Q1 2025 Earnings Report $0.65 -0.05 (-7.70%) As of 10:34 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Live Call not available Live EventEarnings Conference CallBiofrontera Q1 202500:00 / 00:00Live Transcript Follow Audio Biofrontera EPS ResultsActual EPS-$0.47Consensus EPS -$0.14Beat/MissMissed by -$0.33One Year Ago EPSN/ABiofrontera Revenue ResultsActual Revenue$8.59 millionExpected Revenue$10.55 millionBeat/MissMissed by -$1.96 millionYoY Revenue GrowthN/ABiofrontera Announcement DetailsQuarterQ1 2025Date5/15/2025TimeAfter Market ClosesConference Call DateFriday, May 16, 2025Conference Call Time10:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Biofrontera Earnings HeadlinesBiofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update | ...May 15 at 5:47 PM | gurufocus.comBiofrontera Inc. (BFRI) Sees Encouraging Revenue Growth in Q1 | BFRI Stock NewsMay 15 at 5:47 PM | gurufocus.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.May 16, 2025 | Paradigm Press (Ad)Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business UpdateMay 15 at 5:09 PM | globenewswire.comBiofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne VulgarisMay 15 at 12:17 PM | globenewswire.comAn Overview of Biofrontera's EarningsMay 15 at 6:49 AM | benzinga.comSee More Biofrontera Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Biofrontera? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biofrontera and other key companies, straight to your email. Email Address About BiofronteraBiofrontera (NASDAQ:BFRI), a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.View Biofrontera ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum Holds Upcoming Earnings PDD (5/20/2025)Palo Alto Networks (5/20/2025)Synopsys (5/20/2025)Home Depot (5/20/2025)Mitsubishi UFJ Financial Group (5/21/2025)Sumitomo Mitsui Financial Group (5/21/2025)Medtronic (5/21/2025)TJX Companies (5/21/2025)Snowflake (5/21/2025)Lowe's Companies (5/21/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
